X4 Pharmaceuticals outlines expected 2026 Phase 3 trial data release for mavorixafor
Q4 2024 Management View CEO Paula Ragan highlighted 2024 as a transformative year for X4 Pharmaceuticals, with the U.S. approval and launch of XOLREMDI (mavorixafor) for WHIM syndrome, a rare ...
Health on MSN6mon
What To Know about Low White Blood Cell Count (Neutropenia)
To determine if you have neutropenia, your provider will review the test results to determine your absolute neutrophil count ...
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line ...
Medscape21d
FDA Ended Clozapine REMS. But Will It Increase Prescribing?
The ANC testing is part of labeling, as the drug poses a risk for neutropenia. The REMS required that physicians and pharmacists be certified to prescribe and dispense the drug, which was ...
Monthly Prescribing Reference26d
FDA Eliminates Clozapine REMS Program Requirement
Prior to pharmacies dispensing clozapine, the FDA required patients to obtain and report a baseline absolute neutrophil count (ANC) blood test. In order to continue treatment, the ANC was to be ...
Acsh.org15d
The FDA Finally Removes a Huge Barrier to an Effective Schizophrenia Medicine
FDA still recommends that prescribers monitor patients’ ANC according to the monitoring frequencies described in the prescribing information. Information about severe neutropenia will remain in the ...
MedPage Today27d
FDA Eliminates Barrier to Clozapine, Plans to End REMS Program
As part of the overhaul, prescribers will no longer be required to report the results of absolute neutrophil count (ANC) blood tests before pharmacies dispense clozapine to patients. However ...